Bagger Jonatan Ising, Holst Jens Juul, Hartmann Bolette, Andersen Birgitte, Knop Filip Krag, Vilsbøll Tina
Center for Diabetes Research (J.I.B., F.K.K., T.V.), Gentofte Hospital, and NNF Center for Basic Metabolic Research and Department of Biomedical Sciences (J.I.B., J.J.H., B.H., F.K.K.), Faculty of Health Sciences, University of Copenhagen, DK-2900 Hellerup, Denmark; and Diabetes Research Unit (B.A.), Novo Nordisk A/S, DK-2760 Måløv, Denmark.
J Clin Endocrinol Metab. 2015 Dec;100(12):4541-52. doi: 10.1210/jc.2015-2335. Epub 2015 Oct 7.
The gut hormone, oxyntomodulin, is a proglucagon product with body weight-lowering potential. It binds to both the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor; however, the mechanism behind the body weight-lowering effect remains elusive.
We wanted to delineate the contributions of separate and combined GLP-1 receptor and glucagon receptor activation to the body weight-reducing mechanisms of oxyntomodulin.
This was a double-blinded, randomized, crossover study.
The study was conducted at a specialized research unit.
Fifteen young healthy male volunteers (aged 22 [range 18-32] y; body mass index 23 [21-26] kg/m(2); fasting plasma glucose 5.1 [4.4-5.4] mmol/L; and glycated hemoglobin A1c 40 (37-42) mmol/mol).
Five 4-hour liquid meal tests during the infusion of saline, GLP-1 (1 pmol × kg(-1) × min(-1)), glucagon (0.86 pmol × kg(-1) × min(-1)), oxyntomodulin (3 pmol × kg(-1) × min(-1)), or glucagon+GLP-1 (same doses).
We evaluated resting energy expenditure (measured as oxygen uptake, gastric emptying (GE), composite appetite scores (CAS), and food intake.
Oxyntomodulin, GLP-1, and GLP-1+glucagon slowed GE and reduced CAS, whereas glucagon did not affect GE and CAS. All infusions caused a similar decrease in food intake compared with saline (total intake (g [95% confidence interval]), saline 811 [729, 892], GLP-1 669 [586, 750], glucagon 686 [604, 768], oxyntomodulin 689 [608, 771], and glucagon+GLP-1 688 [606, 769]). Oxygen uptake did not change significantly from baseline in response to any peptide infusion compared with saline.
Oxyntomodulin, GLP-1, and glucagon decreased food intake but with no additional effect of combining GLP-1 and glucagon.
肠道激素胃泌酸调节素是一种具有降低体重潜力的胰高血糖素原产物。它能与胰高血糖素样肽-1(GLP-1)受体和胰高血糖素受体结合;然而,其降低体重作用背后的机制仍不清楚。
我们想要阐明单独激活和联合激活GLP-1受体与胰高血糖素受体对胃泌酸调节素减轻体重机制的作用。
这是一项双盲、随机、交叉研究。
该研究在一个专业研究单位进行。
15名年轻健康男性志愿者(年龄22岁[范围18 - 32岁];体重指数23[21 - 26]kg/m²;空腹血糖5.1[4.4 - 5.4]mmol/L;糖化血红蛋白A1c 40[37 - 42]mmol/mol)。
在输注生理盐水、GLP-1(1 pmol×kg⁻¹×min⁻¹)、胰高血糖素(0.86 pmol×kg⁻¹×min⁻¹)、胃泌酸调节素(3 pmol×kg⁻¹×min⁻¹)或胰高血糖素 + GLP-1(相同剂量)期间进行5次4小时的流食试验。
我们评估了静息能量消耗(以摄氧量衡量)、胃排空(GE)、综合食欲评分(CAS)和食物摄入量。
胃泌酸调节素、GLP-1以及GLP-1 + 胰高血糖素减缓了胃排空并降低了综合食欲评分,而胰高血糖素对胃排空和综合食欲评分没有影响。与生理盐水相比,所有输注均使食物摄入量出现类似程度的减少(总摄入量(g[95%置信区间]),生理盐水811[729, 892],GLP-1 669[586, 750],胰高血糖素686[604, 768],胃泌酸调节素689[608, 771],胰高血糖素 + GLP-1 688[606, 769])。与生理盐水相比,任何肽输注后摄氧量与基线相比均无显著变化。
胃泌酸调节素、GLP-1和胰高血糖素均降低了食物摄入量,但GLP-1和胰高血糖素联合使用没有额外效果。